Pfizer axes sickle cell, beta thalassemia deal with Syros
Pfizer terminated a deal that Syros Pharmaceuticals made with Global Blood Therapeutics to develop treatments for beta thalassemia and sickle cell disease.
Under the agreement from 2019, GBT had an exclusive license to develop and commercialize any compounds that resulted from the Syros collaboration. Syros is currently developing candidates for different types of cancer, including myelodysplastic syndromes and acute myeloid leukemia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.